We advised Venus Medtech (Hangzhou) on its placement of new shares

Davis Polk advised Venus Medtech (Hangzhou) Inc. in connection with its placing of 18,042,500 new H shares for an aggregate consideration of approximately HK$1.4 billion (approximately US$188 million). 

Davis Polk also advised Venus Medtech in connection with its HK$2.59 billion (approximately US$331 million) IPO and HK$1.2 billion (approximately US$153 million) placing of new H shares in December 2019 and September 2020, respectively.

Venus Medtech is the leading transcatheter heart valve medical device company in China, focusing on R&D, manufacturing and commercialization of products designed for transcatheter implantation to replace dysfunctional heart valves mainly associated with aortic stenosis and pulmonic, mitral and tricuspid regurgitation. Its self-developed product, VenusA-Valve, is the first TAVR product approved by the NMPA and commercialized in China.

The Davis Polk team included partner Yang Chu and associate Tracy Wu. All members of the Davis Polk team are based in the Hong Kong office. 

Copy link to share post